NCT05801146View on ClinicalTrials.gov

Evaluate the Safety and Efficacy of HG102 as Compared to Botox® in Subject With Moderate to Severe Glabellar Lines

PHASE3RecruitingINTERVENTIONAL
Enrollment

272

Participants

Timeline

Start Date

January 4, 2024

Primary Completion Date

March 31, 2025

Study Completion Date

October 31, 2025

Conditions
Glabellar Lines
Interventions
DRUG

Botulinum Toxin Type A Injection [HG102]

Single administration, Day 0, 20 units

DRUG

Botulinum Toxin Type A Injection [Botox]

Single administration, Day 0, 20 units

Trial Locations (1)

Unknown

RECRUITING

Hugel, Seoul

All Listed Sponsors
lead

Hugel

INDUSTRY